Next Article in Journal
Partial Loss of Inheritable Type I Resistance of Codling Moth to Cydia pomonella granulovirus
Previous Article in Journal
Hypsugopoxvirus: A Novel Poxvirus Isolated from Hypsugo savii in Italy
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessArticle

Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis

1
Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Private Bag X7, Congella, 4013, Durban, South Africa
2
Division of Digestive Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA
3
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
*
Author to whom correspondence should be addressed.
Co-first authors.
Viruses 2019, 11(6), 569; https://doi.org/10.3390/v11060569
Received: 14 May 2019 / Revised: 12 June 2019 / Accepted: 14 June 2019 / Published: 19 June 2019
(This article belongs to the Section Animal Viruses)
  |  
PDF [16965 KB, uploaded 19 June 2019]
  |     |  

Abstract

Intermittent use of a single antiretroviral agent in the presence of a replicating virus could potentially increase the development of antiviral resistance. The pericoital, before-and-after sex, dosing regimen used in the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 tenofovir gel trial meant that women who were infected with hepatitis B virus (HBV) were exposed intermittently to tenofovir during their participation. The impact of this dosing regimen on HBV resistance was assessed by amplification of the HBV polymerase region from 37 stored plasma samples of women who were HBV surface antigen positive. All samples belonged to HBV genotype A. None of the known tenofovir resistance mutations (M240V/I, L180M, A194T, V214A, N238T) were identified in any individuals. While it is reassuring that no resistance mutations were found among women using topical tenofovir, the rapidly expanding access to oral tenofovir-containing HIV pre-exposure prophylaxis (PrEP), with higher systemic exposure to the drug, makes monitoring for potential HBV drug resistance important. View Full-Text
Keywords: hepatitis B virus (HBV); resistance; tenofovir gel; antiretroviral; pre-exposure prophylaxis hepatitis B virus (HBV); resistance; tenofovir gel; antiretroviral; pre-exposure prophylaxis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Baxter, C.; Ngcapu, S.; Blackard, J.T.; Powell, E.A.; Penton, P.K.; Abdool Karim, S.S. Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis. Viruses 2019, 11, 569.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top